Morningstar Investor users sign in here.

Shane Ponraj

Shane Ponraj

 is a Morningstar equity research analyst.

Undervalued ASX healthcare name
Stocks
Undervalued ASX healthcare name
The shares are trading at a 27% discount to our fair value.
Better times ahead for struggling ASX share
Stocks
Better times ahead for struggling ASX share
Revised guidance reflects weak margins but poised for recovery.
Undervalued ASX share proposes merger
Stocks
Undervalued ASX share proposes merger
We view the proposed tie up as value-dilutive but the shares remain undervalued. 
Poor trading update but ASX share still undervalued
Stocks
Poor trading update but ASX share still undervalued
This narrow moat share is still trading below our fair value estimate. 
This ASX share has plunged this year and we think it is cheap
Stocks
This ASX share has plunged this year and we think it is cheap
Investors can overreact to both good and bad news. Overreactions to bad news may present opportunities.
Market is underestimating ASX pathology shares
Stocks
Market is underestimating ASX pathology shares
Morningstar sees several reasons to expect a stronger recover than market consensus.
ResMed’s impressive earnings
Stocks
ResMed’s impressive earnings
Strong device sales and rebound in margin.
Our view on the Sigma / Chemist Warehouse merger
Video
Our view on the Sigma / Chemist Warehouse merger
Is there an opportunity before the ACCC weighs in? 
This cheap ASX share looks 25% undervalued even after 40% rally
Stocks
This cheap ASX share looks 25% undervalued even after 40% rally
Despite advancing from its October low, the undervalued stock of this narrow-moat company may have more room to run.
The cheapest ASX share in our coverage universe
Stocks
The cheapest ASX share in our coverage universe
We still believe this turnaround play is an attractive opportunity after the CEO resigns amid industry challenges. 
of 2
Viewing 1 to 10 of 19